130 related articles for article (PubMed ID: 36764763)
1. Synthesis of SNIPERs against BCR-ABL with kinase inhibitors and a method to evaluate their growth inhibitory activity derived from BCR-ABL degradation.
Cho N; Naito M
Methods Enzymol; 2023; 681():41-60. PubMed ID: 36764763
[TBL] [Abstract][Full Text] [Related]
2. Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands.
Shibata N; Miyamoto N; Nagai K; Shimokawa K; Sameshima T; Ohoka N; Hattori T; Imaeda Y; Nara H; Cho N; Naito M
Cancer Sci; 2017 Aug; 108(8):1657-1666. PubMed ID: 28556300
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase.
Shibata N; Shimokawa K; Nagai K; Ohoka N; Hattori T; Miyamoto N; Ujikawa O; Sameshima T; Nara H; Cho N; Naito M
Sci Rep; 2018 Sep; 8(1):13549. PubMed ID: 30202081
[TBL] [Abstract][Full Text] [Related]
4. Specific non-genetic IAP-based protein erasers (SNIPERs) as a potential therapeutic strategy.
Ma Z; Ji Y; Yu Y; Liang D
Eur J Med Chem; 2021 Apr; 216():113247. PubMed ID: 33652355
[TBL] [Abstract][Full Text] [Related]
5.
Ohoka N; Okuhira K; Ito M; Nagai K; Shibata N; Hattori T; Ujikawa O; Shimokawa K; Sano O; Koyama R; Fujita H; Teratani M; Matsumoto H; Imaeda Y; Nara H; Cho N; Naito M
J Biol Chem; 2017 Mar; 292(11):4556-4570. PubMed ID: 28154167
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents.
Wang C; Zhang Y; Shi L; Yang S; Chang J; Zhong Y; Li Q; Xing D
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1437-1453. PubMed ID: 35589670
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.
Liu H; Ding X; Liu L; Mi Q; Zhao Q; Shao Y; Ren C; Chen J; Kong Y; Qiu X; Elvassore N; Yang X; Yin Q; Jiang B
Eur J Med Chem; 2021 Nov; 223():113645. PubMed ID: 34217059
[TBL] [Abstract][Full Text] [Related]
8. [Development of Protein Knockdown Technology as Emerging Drug Discovery Strategy].
Ohoka N
Yakugaku Zasshi; 2018; 138(9):1135-1143. PubMed ID: 30175757
[TBL] [Abstract][Full Text] [Related]
9. Development of a Potent Protein Degrader against Oncogenic BCR-ABL Protein.
Shibata N; Ohoka N; Hattori T; Naito M
Chem Pharm Bull (Tokyo); 2019; 67(3):165-172. PubMed ID: 30827996
[TBL] [Abstract][Full Text] [Related]
10. Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand.
Demizu Y; Shibata N; Hattori T; Ohoka N; Motoi H; Misawa T; Shoda T; Naito M; Kurihara M
Bioorg Med Chem Lett; 2016 Oct; 26(20):4865-4869. PubMed ID: 27666635
[TBL] [Abstract][Full Text] [Related]
11. Targeted protein degradation and drug discovery.
Naito M
J Biochem; 2022 Jul; 172(2):61-69. PubMed ID: 35468190
[TBL] [Abstract][Full Text] [Related]
12. SNIPERs-Hijacking IAP activity to induce protein degradation.
Naito M; Ohoka N; Shibata N
Drug Discov Today Technol; 2019 Apr; 31():35-42. PubMed ID: 31200857
[TBL] [Abstract][Full Text] [Related]
13. Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor.
Liu H; Mi Q; Ding X; Lin C; Liu L; Ren C; Shen S; Shao Y; Chen J; Zhou Y; Ji L; Zhang H; Bai F; Yang X; Yin Q; Jiang B
Eur J Med Chem; 2022 Dec; 244():114810. PubMed ID: 36306539
[TBL] [Abstract][Full Text] [Related]
14. A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL.
Tong B; Spradlin JN; Novaes LFT; Zhang E; Hu X; Moeller M; Brittain SM; McGregor LM; McKenna JM; Tallarico JA; Schirle M; Maimone TJ; Nomura DK
ACS Chem Biol; 2020 Jul; 15(7):1788-1794. PubMed ID: 32568522
[TBL] [Abstract][Full Text] [Related]
15. Protocols for Synthesis of SNIPERs and the Methods to Evaluate the Anticancer Effects.
Tsukumo Y; Tsuji G; Yokoo H; Shibata N; Ohoka N; Demizu Y; Naito M
Methods Mol Biol; 2021; 2365():331-347. PubMed ID: 34432253
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
El-Damasy AK; Jin H; Seo SH; Bang EK; Keum G
Eur J Med Chem; 2020 Dec; 207():112710. PubMed ID: 32961435
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
[TBL] [Abstract][Full Text] [Related]
18. Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL.
Wang T; Wen T; Li H; Han B; Hao S; Wang C; Ma Q; Meng J; Liu J; Xu H
Int J Nanomedicine; 2019; 14():5581-5594. PubMed ID: 31413564
[TBL] [Abstract][Full Text] [Related]
19. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R
Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139
[TBL] [Abstract][Full Text] [Related]
20. Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.
Zhao Q; Ren C; Liu L; Chen J; Shao Y; Sun N; Sun R; Kong Y; Ding X; Zhang X; Xu Y; Yang B; Yin Q; Yang X; Jiang B
J Med Chem; 2019 Oct; 62(20):9281-9298. PubMed ID: 31539241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
